IGFBP1 and non-small cell lung carcinoma: Furthermore, to further validate the protein expression of PCK1 and IGFBP1 in samples with different clinical efficacy assessments, we performed IHC on samples from 8 NSCLC patients with a partial response (PR) and 7 with progressive disease (PD).